| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCL9L |
| Uniprot No | Q86UU0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1499aa |
| 氨基酸序列 | MRILANKTRLPHPRRREAPGSPPLSPRGHCPPAPAKPMHPENKLTNHGKTGNGGAQSQHQNVNQGPTCNVGSKGVGAGNHGAKANQISPSNSSLKNPQAGVPPFSSLKGKVKRDRSVSVDSGEQREAGTPSLDSEAKEVAPRSKRRCVLERKQPYSGDEWCSGPDSEEDDKPIGATHNCNVADPAMAAPQLGPGQTTQLPLSESSVPGAPHGPPPGLRPDAPGGGGGGGGVPGKPPSQFVYVFTTHLANTAAEAVLQGRADSILAYHQQNVPRAKLDQAPKVPPTPEPLPLSTPSAGTPQSQPPPLPPPPPPAPGSAPPALPPEGPPEDSSQDLAPNSVGAASTGGGTGGTHPNTPTATTANNPLPPGGDPSSAPGPALLGEAAAPGNGQRSLVGSEGLSKEQLEHRERSLQTLRDIERLLLRSGETEPFLKGPPGGAGEGGPPAQAPPPPQQPPTAPPSGLKKYEEPLQSMISQTQSLGGPPLEHEVPGHPPGGDMGQQMNMMIQRLGQDSLTPEQVAWRKLQEEYYEEKRRKEEQIGLHGSRPLQDMMGMGGMMVRGPPPPYHSKPGDQWPPGMGAQLRGPMDVQDPMQLRGGPPFPGPRFPGNQIQRVPGFGGMQSMPMEVPMNAMQRPVRPGMGWTEDLPPMGGPSNFAQNTMPYPGGQGEAERFMTPRVREELLRHQLLEKRSMGMQRPLGMAGSGMGQSMEMERMMQAHRQMDPAMFPGQMAGGEGLAGTPMGMEFGGGRGLLSPPMGQSGLREVDPPMGPGNLNMNMNVNMNMNMNLNVQMTPQQQMLMSQKMRGPGDLMGPQGLSPEEMARVRAQNSSGVMGGPQKMLMPSQFPNQGQQGFSGGQGPYQAMSQDMGNTQDMFSPDQSSMPMSNVGTTRLSHMPLPPASNPPGTVHSAPNRGLGRRPSDLTISINQMGSPGMGHLKSPTLSQVHSPLVTSPSANLKSPQTPSQMVPLPSANPPGPLKSPQVLGSSLSVRSPTGSPSRLKSPSMAVPSPGWVASPKTAMPSPGVSQNKQPPLNMNSSTTLSNMEQGTLPPSGPRSSSSAPPANPPSGLMNPSLPFTSSPDPTPSQNPLSLMMTQMSKYAMPSSTPLYHNAIKTIATSDDELLPDRPLLPPPPPPQGSGPGISNSQPSQMHLNSAAAQSPMGMNLPGQQPLSHEPPPAMLPSPTPLGSNIPLHPNAQGTGGPPQNSMMMAPGGPDSLNAPCGPVPSSSQMMPFPPRLQQPHGAMAPTGGGGGGPGLQQHYPSGMALPPEDLPNQPPGPMPPQQHLMGKAMAGRMGDAYPPGVLPGVASVLNDPELSEVIRPTPTGIPEFDLSRIIPSEKPSSTLQYFPKSENQPPKAQPPNLHLMNLQNMMAEQTPSRPPNLPGQQGVQRGLNMSMCHPGQMSLLGRTGVPPQQGMVPHGLHQGVMSPPQGLMTQQNFMLMKQRGVGGEVYSQPPHMLSPQGSLMGPPPQQNLMVSHPLRQRSVSLDSQMGYLPAPGGMANLPF |
| 分子量 | 157 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"BCL9L promotes colorectal cancer progression through the Wnt/β-catenin signaling pathway"**
- **作者**: Li et al.
- **摘要**: 研究发现BCL9L在结直肠癌中高表达，通过增强β-catenin与TCF的转录复合物稳定性，激活Wnt信号通路，促进肿瘤增殖和转移。
2. **"BCL9L suppresses chemotherapy sensitivity in ovarian cancer via stabilizing HIF-1α under hypoxia"**
- **作者**: Zhang et al.
- **摘要**: 揭示BCL9L在卵巢癌中通过调控缺氧诱导因子HIF-1α的稳定性，促进肿瘤细胞在低氧环境下的存活，导致化疗耐药性增强。
3. **"BCL9L regulates hepatocellular carcinoma metastasis through non-canonical Wnt/PCP signaling"**
- **作者**: Wang et al.
- **摘要**: 提出BCL9L在肝癌中通过非经典Wnt/PCP通路介导上皮-间质转化(EMT)，促进肿瘤细胞侵袭和肝内转移。
4. **"BCL9L cooperates with long non-coding RNA SNHG12 to drive pancreatic cancer progression"**
- **作者**: Kim et al.
- **摘要**: 发现BCL9L与长链非编码RNA SNHG12相互作用，通过抑制E-cadherin表达加速胰腺癌细胞增殖和转移，提示BCL9L作为治疗靶点的潜力。
BCL9L (B-cell chronic lymphocytic leukemia/lymphoma 9-like protein) is a member of the BCL9 protein family, primarily recognized for its role in the Wnt/β-catenin signaling pathway, a critical regulator of embryonic development, stem cell maintenance, and oncogenesis. Structurally, it contains conserved homology domains that facilitate interactions with β-catenin, enhancing transcriptional activation of Wnt target genes. Unlike its paralog BCL9. which is predominantly implicated in solid tumors, BCL9L has been linked to hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and multiple myeloma, though its mechanistic contributions remain less defined. Emerging studies suggest BCL9L may act as a context-dependent oncoprotein or tumor suppressor, influenced by cellular microenvironment and genetic co-factors. In certain cancers, its overexpression correlates with enhanced Wnt pathway activity, promoting cell proliferation and survival, while loss-of-function mutations or epigenetic silencing may drive disease progression through alternative pathways. Recent investigations highlight its potential as a therapeutic target, with strategies focusing on disrupting BCL9L/β-catenin complexes to attenuate oncogenic signaling. However, its dual roles in physiological and pathological processes underscore the need for precision in targeting approaches. Further research is required to unravel its tissue-specific functions and resolve controversies regarding its interplay with BCL9 in Wnt signaling modulation.
×
